Stockreport

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Cogent Biosciences, Inc.  (COGT) 
Last cogent biosciences, inc. earnings: 11/8 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.cogint.com/investor-relations
PDF Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on: 51% week 1 [Read more]